找化学品上960化工网!
960化工网

缬沙坦 | 137863-60-6

缬沙坦结构式图片|137863-60-6结构式图片
缬沙坦
Valsartan
137863-60-6
C24H29N5O3
435.51876
如需查看该化合物的详细结构式,mol文件,smile,InChi 请点击:缬沙坦结构式
60846
简介
缬沙坦是一款血管紧张素II受体拮抗剂抗高血压类药物,该药物是起到使血管紧张素Ⅱ的I型(AT1)受体封闭,血管紧张素Ⅱ血浆水平升高,刺激未封闭的AT2受体,同时抗衡AT1受体的作用,从而达到扩张血管降低血压的效果。 在美国,缬沙坦是一款用于治疗高血压症、充血性心力衰竭、后心肌梗塞的药物。 瑞士汽巴-嘉基公司研发生产的代文缬沙坦于1995年和1996年分别获得美国和欧洲的相关专利权,并于1996年7月首次在德国上市,此后陆续在欧洲、美国、日本上市。 汽巴-嘉基公司与山德士公司在1996年合并成立了诺华公司。缬沙坦具有降血压效果持久稳定,毒副作用小的特点

名称和标识符
InChIKey ACWBQPMHZXGDFX-QFIPXVFZSA-N
Inchi InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
SMILES CCCCC(N([C@H](C(=O)O)C(C)C)CC1C=CC(C2=CC=CC=C2C2=NNN=N2)=CC=1)=O
别名信息
- 中文别名 -
  • 缬沙坦
  • N-(1-戊酰基)-N-[4-[2-(1H-四氮唑-5-基)苯基]苄基]-L-缬氨酸
  • N-乙酰基-3-氯-L-丙氨酸甲酯
  • N-(1-氧代戊基)-N-[[2'-(1H-四氮唑-5-基)[1,1'-联苯]-3-基]甲基]-L-缬氨酸
- 英文别名 -
  • Valsartan
  • 3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic acid
  • (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-3-ylmethyl]-amine
  • 5-(N-acetylamino)indan-1-one
  • 5-Acetamido-1-indanone
  • 5-acetamidoindan-1-one
  • 5-Acetamido-indanone
  • 5-acetylaminoindane-1-one
  • AC1Q1L1Z
  • AG-G-05656
  • N-(1-oxo-2,3-dihydro-1H-inden-5-yl)acetamide
  • N-(1-oxoindan-5-yl)acetamide
  • N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methy]-L-valine
  • NSC225099
  • CHEBI:9927
  • N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
  • SBI-0206738.P001
  • DS-1248
  • BV164506
  • L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]- (9CI)
  • SMR000466318
  • N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
  • ENTRESTO COMPONENT VALSARTAN
  • N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine
  • HMS3651E04
  • (2S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • Spectrum2_001120
  • Prexxartan
  • AKOS015994698
  • VAL-489
  • DAFIRO COMPONENT VALSARTAN
  • C24H29N5O3
  • NSC 758927
  • AB00639940-06
  • KBio2_007423
  • VALSARTAN [INN]
  • NSC-758927
  • EC 604-045-2
  • N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine
  • VALSARTAN COMPONENT OF COPALIA
  • VALSARTAN [MART.]
  • HMS2232F05
  • HSDB 7519
  • VALSARTAN COMPONENT OF COPALIA-HCT
  • VALSARTAN (USP MONOGRAPH)
  • SPECTRUM1505209
  • KBio3_003006
  • AM90287
  • UNII-80M03YXJ7I
  • NC00278
  • (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
  • Tareg
  • (s)-3-methyl-2-[N-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid
  • HMS1922L21
  • (S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • KBioGR_001078
  • HMS2093K22
  • 3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid
  • Valsartan, Pharmaceutical Secondary Standard
  • Certified Reference Material
  • VALSARTAN COMPONENT OF DAFIRO-HCT
  • VALSARTAN [WHO-DD]
  • MLS001424088
  • BYVALSON COMPONENT OF VALSARTAN
  • SW197658-2
  • (5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid
  • VALSARTAN [USP MONOGRAPH]
  • valsartanum
  • VALSARTAN [USP-RS]
  • CHEMBL1069
  • (s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • VALSARTAN COMPONENT OF IMPRIDA-HCT
  • HMS3715P12
  • 137863-60-6
  • Valzaar
  • valsartan (Diovan)
  • BDBM50049186
  • VALSARTAN [EMA EPAR]
  • V0112
  • VALSARTAN (EP IMPURITY)
  • SR-05000001928
  • EXFORGE COMPONENT VALSARTAN
  • DTXCID603735
  • N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(L)-valine
  • EZR-104
  • VALTURNA COMPONENT VALSARTAN
  • Vals
  • (2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
  • NSC758927
  • (S)-3-methyl-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid
  • (S)-3-Methyl-2-{pentanoyl-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • VALSARTAN [USAN]
  • (2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid
  • VALSARTAN [HSDB]
  • Diovan (TN)
  • N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
  • KBio2_002287
  • (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine
  • VALSARTAN COMPONENT OF EXFORGE HCT
  • (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
  • CCG-101028
  • VALSARTAN (MART.)
  • VALSARTAN (USP-RS)
  • AB00639940-08
  • Valsartan, >=98% (HPLC)
  • BSPBio_003501
  • N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine
  • L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
  • N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
  • Spectrum4_000749
  • MLS000759423
  • VALSARTAN COMPONENT OF VALTURNA
  • MFCD00865840
  • (S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • HB3381
  • (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine
  • (2S)-3-Methyl-2-(N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)butanoic acid
  • HY-18204
  • KS-1194
  • N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valine
  • (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
  • s1894
  • VALSARTAN [VANDF]
  • Valpression
  • CGP-48933
  • KBioSS_002289
  • BIDD:GT0345
  • N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine
  • Spectrum_001796
  • D00400
  • COPALIA COMPONENT VALSARTAN
  • DB00177
  • CCG-221275
  • VALSARTAN [EP IMPURITY]
  • C09CA03
  • NCGC00178027-11
  • (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
  • (2R)-3-Methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoic Acid (Valsartan (R)-Enantiomer)
  • VALSARTAN COMPONENT OF DIOVAN HCT
  • BRD-K45158365-001-05-6
  • Varexan
  • VALSARTAN (EP MONOGRAPH)
  • Valsartan, United States Pharmacopeia (USP) Reference Standard
  • CS-1967
  • L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
  • COPALIA-HCT COMPONENT VALSARTAN
  • BRD-K45158365-001-02-3
  • VALSARTAN COMPONENT OF ENTRESTO
  • U35
  • Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard
  • GTPL3937
  • VALSARTAN [ORANGE BOOK]
  • EN300-6482022
  • EXFORGE HCT COMPONENT VALSARTAN
  • (2S)-3-Methyl-2-{N-pentanoyl-N'-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid
  • VALSARTAN COMPONENT OF EXFORGE
  • Valsartan- Bio-X
  • N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
  • AC-4543
  • L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-(9ci)
  • (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
  • (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
  • DAFIRO-HCT COMPONENT VALSARTAN
  • IMPRIDA-HCT COMPONENT VALSARTAN
  • (S)-N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl)-valine
  • Diovan
  • (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
  • valsartan
  • VALSARTAN COMPONENT OF IMMPRIDA
  • AB00639940_11
  • Valsartan (JP17/USP/INN)
  • (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
  • [3H]valsartan
  • 80M03YXJ7I
  • J-007068
  • BCP05184
  • AKOS015914315
  • Valsartan (USAN:USP:INN:BAN)
  • Z1379303659
  • GTPL593
  • Spectrum3_001831
  • Miten
  • Kalpress
  • N-pentanoyl-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-L-valine
  • Spectrum5_001582
  • SPBio_001260
  • Q155472
  • IMPRIDA COMPONENT VALSARTAN
  • KBio2_004855
  • (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoicacid
  • AGSAV301 COMPONENT VALSARTAN
  • L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
  • Nisis
  • DTXSID6023735
  • Provas
  • 3-Methyl-2-{((S)-pentanoyl)-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • Exforge
  • Valsartana
  • Pharmakon1600-01505209
  • ACWBQPMHZXGDFX-QFIPXVFZSA-N
  • 2-{[2''-(2,3-Dihydro-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid
  • DIOVAN HCT COMPONENT VALSARTAN
  • VALSARTAN [EP MONOGRAPH]
  • Valsartan,(S)
  • HMS2051L12
  • NCGC00178027-08
  • Valtan
  • SR-05000001928-1
  • Valsartan, European Pharmacopoeia (EP) Reference Standard
  • 137862-53-4
  • L-Valsartan
  • VALSARTAN [JAN]
  • Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard
  • N-(1-OXOPENTYL)-N-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE
  • CGP 48933
  • SCHEMBL2542
  • N-(1-Oxopentyl)-N-
  • VALSARTAN [MI]
  • VALSARTAN COMPONENT OF BYVALSON
  • AB00639940_09
  • (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-
  • (2S)-3-methyl-2-(N-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)butanoic acid
  • Valsartan [USAN:USP:INN:BAN]
物化性质
实验特性
LogP log Kow = 4.00 (average value)
沸点 684.9 °C at 760 mmHg
熔点 116-117 deg C
闪点 368 °C
密度 1.212
计算特性
精确分子量 435.22703980g/mol
氢键供体数量 2
氢键受体数量 6
可旋转化学键数量 10
同位素质量 435.22703980g/mol
重原子数量 32
复杂度 608
同位素原子数量 0
确定原子立构中心数量 1
不确定原子立构中心数量 0
确定化学键立构中心数量 0
不确定化学键立构中心数量 0
共价键单元数量 1
疏水参数计算参考值(XlogP) 4.4
拓扑分子极性表面积 112Ų
生产方法和用途
用途 用于治疗高血压
专业数据库参考
PubChemId 60846
产品用途
用于治疗高血压
960化工网为您提供缬沙坦专业化合物百科信息,包括中文名,英文名,分子式,分子量,以及该化合物的CasNo.:137863-60-6,和相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等;| WAP 版:137863-60-6
平台客服 平台客服

平台在线客服